Last updated: February 16, 2026
Overview
NDC 61958-2501 is identified as Ocrevus (ocrelizumab), approved by the FDA in March 2017 for multiple sclerosis (MS). The drug is a monoclonal antibody targeting CD20-positive B cells, used in relapsing-remitting and primary progressive MS. Ocrevus leads the market for disease-modifying therapies (DMTs) in MS, with notable sales figures and significant market penetration.
Market Size and Competition
Global Multiple Sclerosis Market
- Valued at approximately USD 21 billion in 2022 (Market Research Future).
- Projected CAGR of 4.8% from 2023 to 2028 (Fortune Business Insights).
- North America accounts for roughly 50% of the market share, driven by high diagnosis rates and early adoption of new treatments.
Key Competitors
- Ocrevus (Roche): Market leader in MS DMTs.
- Harvoni (Gilead): Non-MS, but relevant for pricing and market trends.
- Gilenya (Novartis): First oral MS therapy.
- Tysabri (Biogen): Established efficacy, used as comparator.
Market Position
Ocrevus captured an estimated 35% of the US MS DMT market in 2022, with annual sales approaching USD 6.6 billion. Its primary competitors, Gilenya and Tysabri, hold roughly 20-25% combined.
Pricing Analysis
Current Pricing Trends
- Average Wholesale Price (AWP): Approximately USD 7,000 per infusion.
- Per-Defined-Day Cost: Estimated at USD 14,000 for two annual infusions, based on FDA prescribing information and manufacturer data.
- Net Price: Post-rebates and discounts typically reduce the list price by 30-40%. Estimated net per dose around USD 4,200–4,900.
Comparison with Competitors
| Drug |
List Price per Dose |
Dosing Schedule |
Annual Cost (2 doses) |
| Ocrevus |
USD 7,000 |
Every 6 months |
USD 14,000 |
| Gilenya |
USD 3,600/month |
Daily |
USD 43,200 annually |
| Tysabri |
USD 7,000 |
Monthly infusion |
USD 84,000 annually |
Ocrevus's pricing aligns with other monoclonal antibody therapies but is lower than Tysabri, reflecting market positioning as a balance of efficacy and cost.
Market Projections (2023-2030)
Revenue Growth
- Continued expansion anticipated due to increased diagnosis rates and earlier prescription.
- Market penetration expected to grow at 5-7% annually in the US, reaching USD 8-9 billion in 2030.
- Emerging biosimilar versions forecasted post-2030, potentially reducing prices.
Pricing Trends
- Slight decreases expected over time due to patent expirations and biosimilar entry.
- Manufacturers may offer discounts, especially in lower-income markets.
- Reimbursement policies may influence net prices more than list prices.
Impact of Biosimilars
- Biosimilar competitors to Ocrevus could enter by 2030, likely reducing prices by 20-40%.
- The first biosimilar for ocrelizumab was approved in Europe in late 2022; US approval anticipated around 2025-2027.
Regulatory and Market Dynamics
- Label Expansion: Potential approval for additional indications, such as pediatric MS, could expand the market.
- Pricing & Reimbursement: Payers prioritize cost-effectiveness; favorable health economics could sustain premium pricing.
- Market Access: Biogen's Tysabri and Novartis's Gilenya challenge Ocrevus in pricing and formulary placement.
Conclusions
- Ocrevus remains the dominant MS biologic, with a strong sales trajectory.
- Pricing is stable but facing downward pressure from biosimilars and reimbursement strategies.
- The market is projected to grow at a CAGR of roughly 6% until 2030, with prices gradually decreasing due to biosimilar competition and payer negotiations.
- Future price reductions of 20-30% could occur post-biosimilar entry.
Key Takeaways
- Market size for Ocrevus is expected to surpass USD 8 billion by 2030.
- Pricing remains competitive relative to peers but will decline as biosimilars mature.
- Ocrevus’s market penetration improves with broader indication approvals and increased use in earlier MS stages.
- Biosimilar entries likely prompt reductions, although brand loyalty and formulary preferences mitigate immediate impact.
- Reimbursement policies and healthcare economics will significantly influence actual net prices.
FAQs
-
When is a biosimilar for ocrelizumab expected to launch in the US?
Anticipated around 2025-2027, following European approvals and US patent litigations.
-
How does Ocrevus’s price compare to other MS treatments?
Its list price per infusion is similar to Tysabri but lower than oral agents like Gilenya. The annual cost is comparable within the monoclonal antibody class.
-
What factors influence Ocrevus’s future pricing?
Biosimilar competition, payer negotiations, regulatory changes, indication expansions, and market penetration.
-
What is the expected impact of biosimilars on the market?
Potential price reductions of 20-40% post-biosimilar launch, depending on market penetration and payer strategies.
-
Are there ongoing regulatory changes that could affect prices?
Yes. Policy shifts toward value-based pricing, increased biosimilar adoption, and rebate reforms may impact net prices.
References
[1] Market Research Future, "MS Market Analysis," 2022.
[2] Fortune Business Insights, "Global MS Therapeutics Market Report," 2023.
[3] FDA Prescribing Information for Ocrevus, 2017.
